undamentalytics Newsletter
Sign in

Johnson & Johnson revenue

Johnson & Johnson's revenue was $94.19bn in fiscal 2025, up 6.0% on the year before. Since fiscal 2009 ($61.90bn) it has grown at a compound 2.7% a year. Over the last twelve months it was $99.33bn.

Revenue history

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Jan 20102010Jan 20112011Jan 20122012Dec 20122013Dec 20132014Dec 20142015Jan 20162016Jan 20172017Dec 20172018Dec 20182019Dec 20192020Jan 20212021Jan 20222022Jan 20232023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue61.961.665.067.271.374.370.171.976.581.682.182.678.780.085.288.894.299.3
Growth on the year before—−0.5%+5.6%+3.4%+6.1%+4.2%−5.7%+2.6%+6.3%+6.7%+0.6%+0.6%−4.7%+1.6%+6.5%+4.3%+6.0%—
Gross profit43.542.844.745.649.051.648.550.151.054.554.554.255.355.458.661.463.967.1
Gross margin70.2%69.5%68.7%67.8%68.7%69.4%69.3%69.7%66.7%66.8%66.4%65.6%70.3%69.3%68.8%69.1%67.9%67.6%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 28, 2025
Segments
Line of business Revenue Share YoY
Innovative Medicine $60.4B 64.1% ▲ 6.0%
Med Tech $33.8B 35.9% ▲ 6.1%
Geography
Region Revenue Share YoY
United States $53.8B 57.1% ▲ 6.9%
Outside the US $40.4B 42.9% ▲ 5.0%

From Johnson & Johnson's 10-K filed February 11, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Johnson & Johnson $99.33bn 7.8% 5.9%
Lilly (Eli) $86.46bn 45.5% 39.2%
Merck & Co. $66.57bn 4.6% 4.5%
Pfizer $63.70bn -0.2% -7.0%
Astrazeneca PLC $58.74bn 8.6% —
Bristol Myers Squibb $50.03bn 4.2% 3.6%

Compare with peers

Head to head: JNJ vs LLYJNJ vs MRKJNJ vs PFE

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Johnson & Johnson's SEC filings (10-K and 10-Q), retrieved October 23, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Johnson & Johnson.